Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review.
To NH, Nguyen HQ, Thiolat A, Liu B, Cohen J, Radosevic-Robin N, Belkacemi Y; TransAtlantic Radiation Oncology Network (TRONE) & Association of Radiotherapy, and Oncology of the Mediterranean Area (AROME). To NH, et al. Among authors: radosevic robin n. Breast Cancer Res Treat. 2022 Jun;193(2):265-279. doi: 10.1007/s10549-022-06533-3. Epub 2022 Apr 9. Breast Cancer Res Treat. 2022. PMID: 35397079 Review.
Quantification of HER family receptors in breast cancer.
Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Nuciforo P, et al. Breast Cancer Res. 2015 Apr 9;17:53. doi: 10.1186/s13058-015-0561-8. Breast Cancer Res. 2015. PMID: 25887735 Free PMC article. Review.
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P, Penault-Llorca F, Nabholtz JM. Wang-Lopez Q, et al. Crit Rev Oncol Hematol. 2015 Jul;95(1):88-104. doi: 10.1016/j.critrevonc.2015.02.011. Epub 2015 Mar 4. Crit Rev Oncol Hematol. 2015. PMID: 25900915 Review.
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J. Llombart-Cussac A, et al. Breast Cancer Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4. Breast Cancer Res Treat. 2015. PMID: 26536871 Free PMC article. Clinical Trial.
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Nabholtz JM, Chalabi N, Radosevic-Robin N, Dauplat MM, Mouret-Reynier MA, Van Praagh I, Servent V, Jacquin JP, Benmammar KE, Kullab S, Bahadoor MR, Kwiatkowski F, Cayre A, Abrial C, Durando X, Bignon YJ, Chollet P, Penault-Llorca F. Nabholtz JM, et al. Int J Cancer. 2016 May 1;138(9):2274-80. doi: 10.1002/ijc.29952. Epub 2015 Dec 28. Int J Cancer. 2016. PMID: 26649807 Free article. Clinical Trial.
Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
Dalenc F, Penault-Llorca F, Cohen M, Houvenaeghel G, Piat JM, Liegeois P, Puyuelo L, Suchaud JP, Zouai M, Lacroix-Triki M, Radosevic-Robin N, Benkanoun C, Attar-Rabia H, Chauvet MP, Gligorov J, Belkacemi Y. Dalenc F, et al. Clin Breast Cancer. 2017 Apr;17(2):107-116. doi: 10.1016/j.clbc.2016.08.007. Epub 2016 Aug 31. Clin Breast Cancer. 2017. PMID: 27856201
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B. Leconet W, et al. Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6. Clin Cancer Res. 2017. PMID: 27923843
[Evaluation of the immune infiltrate in breast cancer].
Radosevic-Robin N, Béguinot M, Penault-Llorca F. Radosevic-Robin N, et al. Bull Cancer. 2017 Jan;104(1):52-68. doi: 10.1016/j.bulcan.2016.11.010. Epub 2016 Dec 13. Bull Cancer. 2017. PMID: 27986267 Review. French.
67 results